Last updated on July 2018

Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Dyslipidemia
  • Age: Between 19 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Clinical diagnosis of mixed dyslipidaemia who has high triglycerides and low HDL cholesterol level while LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin monotherapy

Exclusion Criteria:

  • Patients who are hypersensitive (allergic) to peanuts, soybean or any of the ingredients of the medicine
  • Patients who experienced photoallergy or phototoxic reactions during treatment with fibrates or ketoprofen
  • Patients who have active hepatic disorder or have serum transaminase increased continuously without identified reason
  • Patients who have gallbladder disease
  • Patients who have chronic or acute pancreatitis except acute pancreatitis due to severe hypertriglyceridemia
  • Patients who have moderately or severely reduced kidney function(estimated glomerular filtration rate < 60mL/min/1.73m2)
  • Cholib administration combined administration with fibrates, statins, danazol, cyclosporine or strong cytochrome P450(CYP)3A4 inhibitor
  • 145/40mg Cholib Combined administration with amiodarone, verapamil, amlodipine or diltiazem
  • Children <19 years
  • Pregnant or breast-feeding women
  • Patients with biliary cirrhosis
  • Patients who have myopathy and/or previously had rhabdomyolysis or myopathy while taking statins and/or fibrates or had 5 times more creatine phosphokinase than Upper limit of Normal (ULN) while taking statins previously
  • Patients who have rare hereditary problems with lactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption since this drug contains lactose
  • Patients who have rare hereditary problems with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency since this drug contains sucrose
  • Patients who have LDL Cholesterol 130 mg/dL and triglyceride < 150mg/dL and HDL cholesterol 60mg/dL Investigators will refer to the product market authorization (label) for inclusion/exclusion criteria

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.